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41 year old germline and somatic BRCA negative Caucasian female
underwent a total abdominal hysterectomy and bilateral salpingo-oo-
phorectomy for a pelvic mass at the age of 34. Pathology revealed a
serous borderline tumor. The patient presented two years later with
nausea, abdominal pain, and bloating. CT scan revealed a 3 cm mass on
the anterior abdominal wall and a 2 cm mass at the vaginal cuﬀ. She
underwent a secondary optimal tumor debulking with implants re-
moved from the anterior abdominal wall, rectum, sigmoid colon, va-
ginal cuﬀ, and stomach. Pathology showed high grade serous carci-
noma in all tumor implants. She received carboplatin (AUC 6) and nab-
paclitaxel (260mg/m2) every 3 weeks for a total of 6 cycles. Nab-pa-
clitaxel was given after the patient had an allergic reaction to her ﬁrst
dose of paclitaxel. A year after completing chemotherapy, an increasing
CA-125 and CT scan revealed intra-abdominal tumor recurrence. She
underwent 3 cycles of carboplatin (AUC 6) and liposomal doxorubicin
(50mg/m2) with persistently elevated CA-125 levels. Her regimen was
changed to 6 cycles of nab-paclitaxel (260mg/m2) and bevacizumab
(15mg/m2) with normalization of her CA-125 level and no residual
tumor. Nine months later, the patient presented with intra-abdominal
recurrence. She was given 4 cycles of carboplatin (AUC 6) and gemci-
tabine (1000mg/m2) and maintenance q3week topotecan (1.5 mg/m2).
After a year, CA-125 levels started to rise and single agent liposomal
doxorubicin was started with subsequent maintenance aromatase in-
hibitor, Letrozole. Patient was ineligible for clinical trials due to
recurrence in the colon. She developed vaginal bleeding and had
biopsy-conﬁrmed recurrent high grade serous carcinoma at the vaginal
cuﬀ and sigmoid colon. Biopsies were sent for genetic sequencing which
showed an activating HER2/neu alteration (ERBB2 G776_V777).
Genomic results were discussed at a multi-disciplinary molecular tumor
board and afatinib was recommended. The patient started on afatinib
(40mg PO daily) and had a signiﬁcant decrease in her CA-125, decrease
in the size of her vaginal tumor, and resolution of her bleeding. The
patient experienced Grade 1 nausea and a Grade 2 dermatologic rash
but was able to continue on afatinib. The patient had a progression free
interval of ten months on afatinib. The decision was made to restart
nab-paclitaxel (100mg/m2) and bevacizumab (15mg/m2) after an in-
crease in CA-125. The patient has continued on maintenance nab-pa-
clitaxel for the past six months and has had stable CA-125 levels.
2. Discussion
Great eﬀorts are being made to advance the treatment of ovarian
cancer but this malignancy is still the 5th leading cause of cancer-re-
lated death among women in the United States (La Vecchia et al.,
2017). Serous ovarian carcinomas (SOC) comprise 40% of ovarian
neoplasms and are the most common form of this malignancy (La
Vecchia et al., 2017). The lack of obvious symptoms until advanced
stages and the high rate of recurrence greatly contribute to the low
(36%) 5-year survival rate of patients with SOC (La Vecchia et al.,
2017). In light of this data, new approaches to ovarian cancer treatment
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Primary surgical resection is considered the standard treatment for
SOC, with adjuvant chemotherapy oﬀered to patients with Stage 1C
disease or greater (Kampan et al., 2015). The current standard che-
motherapy regimen consists of intravenously administered paclitaxel
(175mg/m2) and carboplatin (AUC 5–7.5) q3 weeks for 6 cycles
(Kampan et al., 2015). Approximately 60% of ovarian cancer patients
will respond to initial treatment with combined paclitaxel-carboplatin,
yet the median progression-free survival (PFS) is only 15months
(Kampan et al., 2015). The eﬃcacy of platinum regimens is dependent
on the treatment-free interval. Patients develop greater platinum re-
sistance, and therefore lower response rates (RR), with shorter intervals
between primary therapy and recurrence (Kampan et al., 2015).
The ﬁeld of targeted therapies for the treatment of EOC has grown
signiﬁcantly in the last ten years. Anti-angiogenic agents are a large
part of this expanding ﬁeld, with bevacizumab being the most well
studied.
The human epidermal growth factor receptor-2 gene (HER-2/
ERBB2) represents another possible target for ovarian cancer based on
its successful use in other malignancies. It encodes tyrosine kinase and
is member of the ERBB receptor family. Dimerization of HER-2 and any
of the ERBB receptors activates a series of signal transduction pathways
involved in cellular proliferation, diﬀerentiation, and migration (Yan
et al., 2014). Due to the nature of this receptor, protein overexpression,
gene ampliﬁcation, and gene mutations induce rapid tumor growth
(Yan et al., 2014).
HER-2 aberrations are common to many tumor types including
breast, colon, endometrium, and lung. Observed frequency of HER-2
positivity in ovarian cancer varies with a range of 1.8–76% (Serrano-
Olvera et al., 2006). Review of molecular tumor data from GOG-111
and GOG-9404 showed HER-2 overexpression in approximately 7% of
EOC cases (Farley et al., 2009) and as high as 12% in serous histologies
(Farley et al., 2009). In these clinical study populations, regardless of
copy number, ERBB2 ampliﬁcation was not correlated with tumor
stage, tumor histology, overall survival (OS), or sensitivity to platinum-
based chemotherapy (Farley et al., 2009).
HER-2 overexpressing tumors are targetable using a variety of anti-
ERBB2 drugs which are currently approved for breast, stomach, and
lung cancers. Non-small cell lung cancer (NSCLC) is now treatable using
afatinib. This ATP-competitive, aniline-quinazoline derivative binds
and irreversibly inhibits signaling from EGFR, HER-2, and HER-4.
Downregulating HER-2 and EGFR phosphorylation inhibits downstream
signaling cascades and induces anti-proliferative eﬀects through cell
cycle G1 arrest and apoptotic cell death. Afatinib is approved as
monotherapy for treatment of locally advanced or metastatic NSCLC
having non-resistant EGFR mutations (https://www.accessda-
ta.fda.gov/drugsatfda_docs/label/2018/201292s014lbl.pdf, n.d.). As
shown in the LUX-LUNG 3 trial, continuous daily dosing of afatinib, at
40–50mg/day in the aforementioned NSCLC patient groups with EGFR
mutation-positive Del19, was found to signiﬁcantly increase RR and
PFS in comparison to the standard six cycle cisplatin-pemetrexed che-
motherapy regimen (Sequist et al., 2013).
With the impressive eﬃcacy of HER-2 targeting therapies in breast,
gastric, and lung cancers, attempts are being made to achieve similar
eﬃcacy for ovarian cancer. Trastuzumab, a HER-2 monoclonal anti-
body that binds the extracellular domain of EGFR, showed success in
the treatment of HER-2 positive breast cancer. Due to its eﬃcacy, the
Gynecologic Oncology Group initiated a phase II trial of single agent
trastuzumab for patients with recurrent or refractory ovarian carci-
noma. Unfortunately, the low response rate of 7.3% limits the utility of
this agent as a monotherapy (Bookman et al., 2003). Similarly, pertu-
zumab, another HER-2 antibody used in the treatment of breast cancers,
was found to signiﬁcantly increase RR and PFS when combined with
gemcitabine in platinum-resistant ovarian cancers (Makhija et al.,
2010).
The eﬀectiveness of afatinib likely depends on a number of diﬀerent
clinical and molecular factors that have yet to be identiﬁed. As an ex-
ample, the Carvajal-Hausdorf study identiﬁed cases of HER2 ampliﬁ-
cation showing diﬀering levels of intracellular (ICD) and extracellular
domains (ECD) (Carvajal-Hausdorf et al., 2017). Because HER2 targeted
agents are directed against the HER2 ICD or ECD, these ﬁndings suggest
that targeted HER2 agents may need to be tailored to the speciﬁc do-
main levels present.
For the patient in this case, afatinib was chosen as treatment due to
the presence of an activating mutation in HER2. This use is an extra-
polation of the results from the LUX-Lung trial in NSCLC. We have
presented this case to demonstrate anecdotal eﬀectiveness of targeting
HER2/neu activation in patients with ovarian cancer and a HER2 ac-
tivating tumor mutation.
3. Conclusion
Commercially available genomic sequencing can be used to guide
individual treatment plans for primary or recurrent malignancies and
should be based on the activating mutations present in the tumor.
Her2/neu mutations are an eﬀective target in lung cancers and afatinib
is an eﬀective targeting agent. Larger clinical trials are needed to assess
the eﬀectiveness of afatinib in ovarian cancer patients and to identify
the speciﬁc sub-populations in which it may be most eﬀective. Due to
the rarity of this mutation in ovarian cancer, this may require a basket
trial study that would assess use of afatinib or other HER2 targeting
small molecule inhibitors in tumor types with activating HER2 muta-
tion.
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